Some additional cytogenetic aberrations in patients treated with Imatinib (STI571)

被引：0
|
作者：
Salamanczuk, Z. [1 ]
Jakobczyk, M. [1 ]
Sacha, T. [1 ]
Skotnicki, A. B. [1 ]
机构：
[1] Jagiellonian Univ, Dept Haematol, PL-31007 Krakow, Poland
来源：
CHROMOSOME RESEARCH | 2005年 / 13卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [41] Imatinib mesylate (STI571; Glivec) -: a new approach in the treatment of biliary tract cancer?
    Weidmann, M
    Kreth, F
    Feisthammel, J
    Deininger, M
    Mössner, J
    Caca, K
    ANTI-CANCER DRUGS, 2003, 14 (09) : 751 - 760
  • [42] Imatinib mesilate (STI571; GleevecR):: A new approach in the treatment of bilary tract cancers?
    Wiedmann, MW
    Mössner, J
    Caca, K
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6244S - 6244S
  • [43] The effect of Gleevec (STI571;imatinib mesylate) in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with secondary chromosomal aberrations.
    Mohamed, AN
    Pemberton, P
    Zonder, JA
    Homisha, S
    Ford, J
    Schiffer, CA
    BLOOD, 2001, 98 (11) : 560A - 560A
  • [44] Imatinib mesylate (STI571) inhibition of malignant glioma cells is increased by modulation of the MAPK pathway
    Ren, H
    Walker, C
    Pazmany, L
    Pelech, S
    Rainov, N
    NEURO-ONCOLOGY, 2005, 7 (03) : 387 - 387
  • [45] The Effects of Genistein and STI571 (Imatinib) on Signal Protein Levels Affecting Chronic Myeloid Leukemia
    Armutcuoglu, Nur Erden
    Kasap, Yesim Korkmaz
    Yurtcu, Erkan
    GAZI MEDICAL JOURNAL, 2018, 29 (03): : 187 - 190
  • [46] Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia
    Hofmann, WK
    Komor, M
    Hoelzer, D
    Ottmann, OG
    LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 655 - 660
  • [47] c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571)
    Hotfilder, M
    Lanvers, C
    Jürgens, H
    Boos, J
    Vormoor, J
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (02) : 167 - 169
  • [48] c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571)
    Marc Hotfilder
    Claudia Lanvers
    Heribert Jürgens
    Joachim Boos
    Josef Vormoor
    Cancer Chemotherapy and Pharmacology, 2002, 50 : 167 - 169
  • [49] Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia
    Legros, L
    Bourcier, C
    Jacquel, A
    Mahon, FX
    Cassuto, JP
    Auberger, P
    Pagès, G
    BLOOD, 2004, 104 (02) : 495 - 501
  • [50] Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients
    Valeyrie, L
    Bastuji-Garin, S
    Revuz, J
    Bachot, N
    Wechsler, J
    Berthaud, P
    Tulliez, M
    Giraudier, S
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (03) : 761 - 761
12345